In highly invasive breasts cancer cells (MDA-MB-231), TGF-β1-treatment increased the expression of RECK at the mRNA level but diminished the RECK protein levels p38 but not ERK1/2 dependent pathways inhibition, blocked the TGF-β1-mediated increase of RECK mRNA expression. This evidence concerns the gene TGFB1 and breast cancer.